RBRoberto Bertorelli

Roberto Bertorelli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roberto Bertorelli has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Data from Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Supplementary Figures from S1 to S23 and Supplementary tables from S1 to S3

  • Open Access

    Data from Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Neuroblastoma (NB) is an aggressive childhood tumor, with high-risk cases having a 5-year overall survival probability of approximately 50%. The multimodal therapeutic approach for NB includes treatment with the retinoid isotretinoin (13-cis retinoic acid; 13cRA), which is used in the post-consolidation phase as an antiproliferation and prodifferentiation agent to minimize residual disease and prevent relapse. Through small-molecule screening, we identified isorhamnetin (ISR) as a synergistic compound with 13cRA in inhibiting up to 80% of NB cell viability. The synergistic effect was accompanied by a marked increase in the expression of the adrenergic receptor α1B (ADRA1B) gene. Genetic knockout of ADRA1B or its specific blockade using α1/α1B adrenergic antagonists led to selective sensitization of MYCN-amplified NB cells to cell viability reduction and neural differentiation induced by 13cRA, thus mimicking ISR activity. Administration of doxazosin, a safe α1-antagonist used in pediatric patients, in combination with 13cRA in NB xenografted mice exerted marked control of tumor growth, whereas each drug alone was ineffective. Overall, this study identified the α1B adrenergic receptor as a pharmacologic target in NB, supporting the evaluation of adding α1-antagonists to the post-consolidation therapy of NB to more efficiently control residual disease.Significance:Targeting α-adrenergic receptors synergizes with isotretinoin to suppress growth and to promote differentiation of neuroblastoma, revealing a combinatorial approach for more effective management of the disease and prevention of relapse.

  • Open Access

    Profibrotic Molecules Are Reduced in CRISPR-Edited Emery–Dreifuss Muscular Dystrophy Fibroblasts

    by Eleonora Cattin, Elisa Schena, Elisabetta Mattioli, Stefania Marcuzzo, Silvia Bonanno, Paola Cavalcante, Federico Corradi, Daniela Benati, Giorgia Farinazzo, Marco Cattaneo, et al.

    Emery–Dreifuss muscular dystrophy (EDMD) is caused by mutations in EMD, LMNA, SYNE1, SYNE2, and other related genes. The disease is characterized by joint contractures, muscle weakening and wasting, and heart conduction defects associated with dilated cardiomyopathy. Previous studies demonstrated the activation of fibrogenic molecules such as TGFbeta 2 and CTGF in preclinical models of EDMD2 and increased secretion of TGFbeta 2 in patient serum. A wide screening of patient cells suggested fibrosis, metabolism, and myogenic signaling as the most affected pathways in various EDMD forms. In this study, we show that alpha-smooth muscle actin-positive myofibroblasts are overrepresented in patient fibroblast cultures carrying EMD, LMNA, or SYNE2 mutations, and profibrotic miRNA-21 is upregulated. Upon CRISPR/Cas correction of the mutated EMD or LMNA sequence in EDMD1 or EDMD2 fibroblasts, respectively, we observe a reduced expression of fibrogenic molecules. However, in patient myoblasts, neither fibrogenic proteins nor miRNA-21 were upregulated; instead, miRNA-21-5p was downregulated along with muscle-specific miRNA-133b and miRNA-206, which have a crucial role in muscle cell homeostasis. These observations suggest that the conversion of laminopathic fibroblasts into a profibrotic phenotype is a determinant of EDMD-associated muscle fibrosis, while miRNA-206-dependent defects of laminopathic myoblasts, including altered regulation of VEGF levels, contribute to muscle cell deterioration. Notably, our study provides a proof-of-principle for the application of gene correction to EDMD1 and EDMD2 and presents EDMD1 isogenic cells that exhibit an almost complete rescue of a disease-specific miRNA signature. These cells can be used as experimental models for studying muscular laminopathies.


  • Open Access

    Restored Collagen VI Microfilaments Network in the Extracellular Matrix of CRISPR-Edited Ullrich Congenital Muscular Dystrophy Fibroblasts

    by Daniela Benati, Eleonora Cattin, Federico Corradi, Tommaso Ferrari, Eleonora Pedrazzoli, Clarissa Patrizi, Matteo Marchionni, Roberto Bertorelli, Veronica De Sanctis, Luciano Merlini, et al.

    Collagen VI is an essential component of the extracellular matrix (ECM) composed by α1, α2 and α3 chains and encoded by COL6A1, COL6A2 and COL6A3 genes. Dominant negative pathogenic variants in COL6A genes result in defects in collagen VI protein and are implicated in the pathogenesis of muscular diseases, including Ullrich congenital muscular dystrophy (UCMD). Here, we designed a CRISPR genome editing strategy to tackle a dominant heterozygous deletion c.824_838del in exon 9 of the COL6A1 gene, causing a lack of secreted collagen VI in a patient’s dermal fibroblasts. The evaluation of efficiency and specificity of gene editing in treating patient’s fibroblasts revealed the 32% efficiency of editing the mutated allele but negligible editing of the wild-type allele. CRISPR-treated UCMD skin fibroblasts rescued the secretion of collagen VI in the ECM, which restored the ultrastructure of the collagen VI microfibril network. By using normal melanocytes as surrogates of muscle cells, we found that collagen VI secreted by the corrected patient’s skin fibroblasts recovered the anchorage to the cell surface, pointing to a functional improvement of the protein properties. These results support the application of the CRISPR editing approach to knock out COL6A1 mutated alleles and rescue the UCMD phenotype in patient-derived fibroblasts.


  • Open Access

    Data from Alpha-1 adrenergic antagonists sensitize neuroblastoma to therapeutic differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Neuroblastoma (NB) is an aggressive childhood tumor, with high-risk cases having a 5-year overall survival probability of approximately 50%. The multimodal therapeutic approach for NB includes treatment with the retinoid isotretinoin (13-cis retinoic acid; 13cRA), which is used in the post-consolidation phase as an anti-proliferation and pro-differentiation agent to minimize residual disease and prevent relapse. Through small molecule screening, we identified isorhamnetin (ISR) as a synergistic compound with 13cRA in inhibiting up to 80% of NB cell viability. The synergistic effect was accompanied by a marked increase in the expression of the adrenergic receptor α1B (ADRA1B) gene. Genetic knockout of ADRA1B or its specific blockade using ɑ1/ɑ1B adrenergic antagonists led to selective sensitization of MYCN-amplified NB cells to cell viability reduction and neural differentiation induced by 13cRA, thus mimicking ISR activity. Administration of doxazosin, a safe α1-antagonist used in pediatric patients, in combination with 13cRA in NB xenografted mice exerted marked control of tumor growth, while each drug alone was ineffective. Overall, this study identified the α1B adrenergic receptor as a pharmacological target in NB, supporting the evaluation of adding α1-antagonists to the post-consolidation therapy of NB to more efficiently control residual disease.

  • Open Access

    Supplementary Data from Alpha-1 adrenergic antagonists sensitize neuroblastoma to therapeutic differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Supplementary Figures from S1 to S23 and Supplementary tables from S1 to S3

  • Open Access

    Supplementary Data from Alpha-1 adrenergic antagonists sensitize neuroblastoma to therapeutic differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Supplementary Figures from S1 to S23 and Supplementary tables from S1 to S3

  • Open Access

    WITHDRAWN: DNA polymerase λ-driven targeted mutagenesis for directed evolution in human cells

    by Davide Aiello, Matteo Ciciani, Federica Marelli, Marta Stancampiano, Veronica De Sanctis, Roberto Bertorelli, Eyemen Gafar Ali Kheir, Giulia Maule, Anna Cereseto, Daniele Arosio

    Withdrawal Statement: The authors have withdrawn this manuscript due to the need for further modifications in the experimental setup. Therefore, the authors do not wish this work to be cited as reference for this project. If you have any questions, please contact the corresponding author.

  • Open Access

    Data from Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Neuroblastoma (NB) is an aggressive childhood tumor, with high-risk cases having a 5-year overall survival probability of approximately 50%. The multimodal therapeutic approach for NB includes treatment with the retinoid isotretinoin (13-cis retinoic acid; 13cRA), which is used in the post-consolidation phase as an antiproliferation and prodifferentiation agent to minimize residual disease and prevent relapse. Through small-molecule screening, we identified isorhamnetin (ISR) as a synergistic compound with 13cRA in inhibiting up to 80% of NB cell viability. The synergistic effect was accompanied by a marked increase in the expression of the adrenergic receptor α1B (ADRA1B) gene. Genetic knockout of ADRA1B or its specific blockade using α1/α1B adrenergic antagonists led to selective sensitization of MYCN-amplified NB cells to cell viability reduction and neural differentiation induced by 13cRA, thus mimicking ISR activity. Administration of doxazosin, a safe α1-antagonist used in pediatric patients, in combination with 13cRA in NB xenografted mice exerted marked control of tumor growth, whereas each drug alone was ineffective. Overall, this study identified the α1B adrenergic receptor as a pharmacologic target in NB, supporting the evaluation of adding α1-antagonists to the post-consolidation therapy of NB to more efficiently control residual disease.Significance:Targeting α-adrenergic receptors synergizes with isotretinoin to suppress growth and to promote differentiation of neuroblastoma, revealing a combinatorial approach for more effective management of the disease and prevention of relapse.

  • Open Access

    Supplementary Data from Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Supplementary Figures from S1 to S23 and Supplementary tables from S1 to S3